AI Research Insights

GLP-1 and dual agonists benefit cardiometabolic diseases with proven CV and renal protection.

Deep learning boosts MRI-based NPC detection, segmentation and radiotherapy planning.

EBV status shapes NPC genomics, immunity and personalized treatment strategies.

Multiple salvage options exist for recurrent NPC with distinct pros and cons.

Two PD-1 combinations improve survival for recurrent metastatic NPC with distinct toxicities.

Circulating EBV DNA enables effective early screening and mortality reduction for NPC.

AI boosts MRCP accuracy for distinguishing benign and malignant biliary strictures.

Liver flukes trigger CCA via inflammation, DNA damage and epigenetic changes.

Lenvatinib shows distinct efficacy, safety and dosing differences between trials and real-world use.

Three targeted drugs for CCA differ in efficacy, safety, resistance and medication sequence.

CCA subtypes differ greatly in molecular alterations, assays and targeted therapies.

Two chemoimmunotherapies become new standards for advanced BTC with distinct trial profiles.

Durvalumab/pembrolizumab plus GC are first-line standards for advanced BTC with comparable efficacy.

AS matches lobectomy safety for low-risk PTMC with fewer complications and superior QoL.

DTP triplet therapy boosts efficacy yet needs randomized trials for solid validation in BRAF-mutant ATC.

PTC surge in China/US driven mostly by overdiagnosis, not true disease rise

IMDC stratifies ccRCC; China and US differ in approved regimens and sequencing.

Controversies in early TGCT focus on surveillance vs chemo, plus salvage strategy choices.

IO-TKI for rapid control, IO-IO for durable long-term survival in ccRCC.